logo
Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety

Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety

Business Wire6 days ago
BASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has launched its fourth annual global art competition in support of World Diabetes Day 2025. This year, the competition is themed around Diabetes and Anxiety, shining a spotlight on the mental health impact of diabetes and capturing the unfiltered reality of living with the condition.
An estimated 3 in 4 people living with diabetes have experienced anxiety, depression or another mental health condition as a result of managing their diabetes i. With the number of people affected by diabetes expected to rise to over 850 million by 2050 ii, this year's This is Diabetes. This is Anxiety. campaign aims to raise awareness and deepen understanding through creativity and storytelling.
Submissions are now open globally and free to enter at www.thisisdiabetes.com until October 24, 2025, with the winners announced on World Diabetes Day, a global initiative of the International Diabetes Federation (IDF), held each year on November 14.
Koichiro Sato, CEO of Ascensia Diabetes Care and Chief Operating Officer and Chief Strategy Officer of Ascensia's parent company PHC Group, commented:
'World Diabetes Day is a key moment for us to support the global diabetes community. For 2025, we want to shed light on the emotional burden that often goes unseen. The theme of 'This is Diabetes. This is Anxiety.' is deeply important, and we hope this competition provides an outlet for expression, connection and better quality of life.'
'Each year we are inspired by the stories shared through art,' he continued. 'We invite artists, supporters, and advocates to help us show the world what anxiety and diabetes truly look like. Every submission adds to a collective story that deserves to be seen and heard.'
In addition to showcasing the Top 20 submissions across Ascensia's platforms, the 2025 competition will introduce a free downloadable coloring-in booklet featuring selected artwork. This new initiative is designed to spark creativity, reflection and learning for individuals and families alike.
Prizes include donations of €6,000, €3,000 and €1,000 made in the winners' names to a diabetes charity of their choice. A diverse judging panel – including global artists, diabetes advocates, and Ascensia employees – will evaluate submissions based on creativity, emotional impact, connection to the theme, and storytelling.
Now in its fourth year, the competition builds on the momentum of previous This is Diabetes campaigns, which have drawn over 500 entries and delivered donations to diabetes charities on four continents.
Ascensia Diabetes Care is a PHC Holdings Corporation (TSE: 6523) company. Terms and conditions apply.
Notes for Editors
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR ® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: www.ascensia.com
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service precision technology across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries. www.phchd.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

Yahoo

time41 minutes ago

  • Yahoo

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the 'Company'), today announced the filing, for the semester ended June 30, 2025, of its Half-Year Report with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). The 2025 Half-Year Report can be consulted or downloaded from the Company's website ( in the section Investors/Financial Information, and on the AMF website ( in French only. It is also available free of charge upon request: - by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ; - by email: investors@ About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactBrett WhelanDBV Attachment PDF VersionSign in to access your portfolio

InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025
InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025

Business Wire

time42 minutes ago

  • Business Wire

InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Holdings, Inc. (NYSE American: INFU) ('InfuSystem' or the 'Company'), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company's website at A replay of the call will be available by visiting for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, replay access code 5094847 through Tuesday, August 12, 2025. About InfuSystem Holdings, Inc. InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025
Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

Yahoo

timean hour ago

  • Yahoo

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

HAYWARD, Calif., July 29, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. View source version on Contacts Investors: Pulse Biosciences, Skinner, CFOIR@ Or Gilmartin GroupPhilip Trip Taylor415.937.5406philip@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store